Hindricks G, Kottkamp H, Willems S, Chen X, Wichter T, Haverkamp W, Yli-Mäyry S, Breithardt G, Borggrefe M
Medizinische Klinik und Poliklinik, Universitätsklinik Münster.
Z Kardiol. 1995;84 Suppl 2:103-21.
Radiofrequency catheter ablation has been established as a first line therapy for the curative treatment of patients with atrioventricular nodal reentrant tachycardia and atrioventricular tachycardia encompassing accessory pathways as well as for ablation of the "normal" AV-junction. For these indications, the success rates exceed 90%. Acute complications during ablation of accessory pathway and ablation of the "normal" AV-junction occur in approximately 2-5% of patients treated. The incidence of complications during modification of the atrioventricular node to cure AV-nodal reentrant tachycardias clearly depends on the ablation technique used. The anterior approach with ablation of the so-called "fast pathway" carries a significantly higher risk of complete AV-block when compared to the inferior approach (so-called "slow pathway ablation") (approximately 4-8% vs. 2%). Arrhythmia recurrence after successful ablation of the "normal" AV-junction occurs only rarely, while the recurrence rate after modification of the AV-node or ablation of accessory pathway is approximately 10% during long-term follow-up. Recently, it has been shown that other, rare types of supraventricular tachycardia (sinus-atrial reentrant tachycardia, ectopic atrial tachycardia, human type I atrial flutter) can also be successfully ablated using radiofrequency current. In addition, first clinical results indicate that modification of anterograde AV-nodal conduction properties in patients with atrial fibrillation and fast ventricular rate by radiofrequency application to postero- and midseptal sites might be a useful therapeutic tool to slow ventricular rate. Because of the high success-rate and the relative low incidence of severe procedure related complications, the indications of radiofrequency ablation procedures for the treatment of supraventricular tachycardias will be extended in the future. In addition, it might be reasonable to expect that during the next years, all types of supraventricular tachycardia, except atrial fibrillation, can be targeted and cured by radiofrequency ablation in the majority of cases.
射频导管消融术已成为治疗房室结折返性心动过速、包含旁路的房室性心动过速以及消融“正常”房室交界区患者的一线根治性疗法。对于这些适应证,成功率超过90%。在消融旁路和“正常”房室交界区时,约2 - 5%接受治疗的患者会出现急性并发症。通过改变房室结来治愈房室结折返性心动过速时并发症的发生率显然取决于所使用的消融技术。与下侧入路(所谓的“慢径路消融”)相比,采用前侧入路消融所谓的“快径路”导致完全性房室传导阻滞的风险显著更高(约4 - 8%对2%)。成功消融“正常”房室交界区后心律失常复发的情况很少见,而在长期随访中,改变房室结或消融旁路后的复发率约为10%。最近研究表明,其他罕见类型的室上性心动过速(窦房结折返性心动过速、异位房性心动过速、I型心房扑动)也可通过射频电流成功消融。此外,初步临床结果表明,通过对后间隔和中隔部位施加射频来改变心房颤动且心室率快的患者的房室结前向传导特性,可能是减慢心室率的一种有效治疗手段。由于成功率高且与手术相关的严重并发症发生率相对较低,未来射频消融术治疗室上性心动过速的适应证将会扩大。此外,可以合理预期,在未来几年,除心房颤动外的所有类型室上性心动过速在大多数情况下都可通过射频消融术进行靶向治疗并治愈。